Subscribe to Money Morning get daily headlines subscribe now! Money Morning Private Briefing today's private briefing Access Your Profit Alerts

biotech investing

  • Featured Story

    immunotherapy

    Cancer is of course one of the most challenging pathologies patients and doctors can face; the disease cells are fiendishly adaptive as the body tries to fight them off, making them stronger.

    Until very recently, medicine's best shot at fighting cancer was to bombard the patient with harsh, poisonous chemicals or radiation in the hope that the illness died before the body.

    But science is poised to turn the page on this disease, with some novel breakthroughs in the past few years, and new therapies that show a great deal of promise in fighting previously intractable cancers, making some of these deadly diseases treatable or even curable.

    In fact, it's immuno-oncology, the newest form of immunotherapy, that's making the fastest strides.

    Wall Street concurs. According to Allied Market Research, the immuno-oncology market has been growing at a solid 7.1% annual clip since 2014, and it's expected to hit $110 billion by 2020.

    My read on this is: That's a very conservative number. I'll show you how big I think it's actually going to be, but that's not even the best part...

    You see, this company's therapy hasn't even made its full impact yet, but it's already paying one of the richest dividends on the market, and for value, it's unbeatable...

Article Index

How to Make 69% Off the Biotech Stock Rebound

biotech stocks

Despite the recent slump, the life sciences sector - which includes biotech - offers investors some of the best long-term opportunities for building wealth.

And that means you definitely want biotech stocks in your portfolio, especially now.

The market is already bouncing back. And that means the three plays I'm going to tell you about are poised to hand investors 69% on average...

Why Biotech Stocks Will Outperform in 2016 – and Our Top Pick

best biotech ETF

Biotech stocks have stalled in 2016 along with the broader markets, with the iShares Nasdaq Biotech ETF (Nasdaq: IBB) down 24.43% year to date.

Still, Money Morning Biotech Investing Specialist Ernie Tremblay says the sector will outperform in 2016. And he's pinpointed one foundational play that's already climbed 14% in the last five days.

But first, here's why biotech stocks are presenting a huge opportunity right now...

How to Make a (Consistent) Killing in Biotech Investing in 2016

Biotech is in the midst of its longest bull run in history, and there's every reason to expect it will remain an attractive outperformer this year.

Our Biotech Investing Specialist Ernie Tremblay is going to tell you everything you need to know to make a killing in biotech investing in 2016.

Ekso Stock – Better to Be Early Than Bail Because You're Impatient

esko bionics

As you might expect, my email's been flooded with all kinds of questions, comments, and observations since the markets began their 7% slide downward in earnest.

Most are pretty straightforward - oil, the sell-off, China, Social Security, and more - but a number of them deal with our favorite Human Augmentation recommendation, Ekso Bionics.

One, in particular, was exceptionally blunt: Have we backed the wrong horse?

Nope. Here's how Ekso stock could lead to 2,000% gains for patient investors.

Biotech Stocks Have Now Reached Bear Market Territory

biotech stocks

The S&P 500 has dropped 3.8% since the end of July, but that's nothing compared to the losses we've seen from biotech stocks.

In fact, this week's latest pullback has many biotech stocks in bear market territory.

Here's just how far they've fallen...

Biotech Investing Buff Just Made $1.1 Billion Profit in 8 Months – Here's How

Biotech Investing

With a net worth of $12.6 billion, Patrick Soon-Shiong, MD, is the world's richest doctor, the richest American in the healthcare industry, and the 96th-richest person on the planet in 2015 according to Forbes.

And just in August, the 63-year-old became $1.1 billion richer -- from a move he'd made only eight months prior, according to Bloomberg...

Here's Soon-Shiong's story - plus five ways you can cash in with biotech profits of your own...

Two Tactics for Bigger Biotech Investing Profits

Biotech

Over the past six months, we've seen the Nasdaq Biotechnology Index, an indicator for the entire sector, take some wild swings up and down, often by as much as 10% from week to week.

That's in stark contrast to the previous half-year, when we experienced a relatively steady upward swell.

This year's unsettling international headlines haven't helped. In just the last few months, we've battled doom-and-gloom sentiment on the debt crisis in Greece, currency manipulation in China, cratering oil prices, the burgeoning debt crisis in Puerto Rico, and the specter of a September rate hike from the Fed.

There is good news: This turbulence isn't insurmountable. And the simple tactics I'm about to share with you could dramatically improve your profits in this choppy market...

How This Biotech Stock Gained Over 3,000% and Trapped Investors

For biotech stock investors, what happened to Aquanox Pharmaceuticals Inc. (Nasdaq: AQXP) over the past week looked like the ultimate fantasy come true.

After reporting positive results from a mid-stage test for its bladder pain syndrome/interstitial cystitis drug AQX-1125 on Aug. 7, Aquanox stock took off like a rocket. At one point it was up more than 3,000%.

Here's the reason Aquanox stock acted so crazily - and what made it ripe to become a trap for retail investors...

This Bioscience Company Has "Nearly Limitless" Income Potential

Medical device companies can be profit-making machines - one manufacturer of magnetic resonance imaging (MRI) machines and other high-tech products is up more than 250% over the past 12 months, for instance.

Most of them make their living by staying on the leading edge of innovation, producing some of the coolest gadgets you can imagine.

And, even better, they can deliver some of the most impressive gains in the bioscience industry to their shareholders.

The good performance of these manufacturers gives you some idea of the potential we're dealing with here.

Just look at these soaring share prices...

This Cannabis Biotech Leader Helped Us Beat the Market by More Than 620%

biotech

Back on March 27, 2014, I recommended that Money Morning Members pick up what I felt was the very best play in the burgeoning cannabis biotech industry.

Today, the shares have done even better than I imagined, which is why I wanted to touch base with you again.

And if you missed this stock last year - no worries. We'll start you now as it continues its run - a run that took off while "popular" medical marijuana stocks cratered.

Here's how we'll do it...

Now's Our Chance to Play This Month's Best IPO

upcoming ipos Editor's Note: Normally this intelligence would go to paid-up members of Bill's Private Briefing, but this debut is going to be so big, and the medicine so important, that he wanted to give everyone a chance to tap this $21 billion market. The shares start trading on Thursday, Aug. 6, so there's some time to […]

Read More…

[Chart] Pharma Companies Make Billions as Prescription Spending Soars

Biotech Investing

Prescription drug spending continues to hit record highs, and the world's top pharma companies continue to bank billions.

More than $374 billion was spent on prescription drugs in the United States in 2014, according to a report from the IMS Institute of Health. That was a 13.1% jump from 2013, and the highest growth rate in more than a decade, says ExpressScripts.

Here's a look at how U.S. prescription drug spending has trended over the last 10 years..

These Promising Cancer Therapies Are a Biotech "Triple Play"

On Jan. 7, 2015, CytRX Corp. announced positive results from a study of its experimental brain cancer drug, aldoxorubicin, and the company's stock immediately jumped 15.8%. Then, over the next four months, it nearly doubled.

Over the months since June 2013, when Clovis Oncology released positive trial data for both a lung cancer and a lymphoma drug, CLVS share value has soared 255%.

And just last summer, when Puma Biotechnology released positive results from a clinical trial of its breast cancer drug, neratanib, PBYI shares jumped 300% in a single session.

It's clear that investors can do very well with the right cancer drug.

But there, of course, is the rub: Finding the right cancer drug is not so easy.

I'm about to show you three companies - all sound investments - running strong in the race to fight this scourge, and the one that could very well take the prize...

The Best Biotech ETF to Buy in 2015

Biotech etf

Biotech stocks have seriously outperformed the markets in 2015, and our favorite biotech ETF has been one of the biggest winners.

In the last year, the Nasdaq Biotechnology Index has soared 48.3%. The Dow and S&P 500 are up just 7.3% and 8.6% in that time.

Here's our favorite biotech ETF to buy now...

"21st Century Cures" Could Revolutionize Biotech

No one is thrilled with the way new drugs and medical devices come to market in the U.S. - not the biotech and pharmaceutical companies, not the regulators at the Food and Drug Administration (FDA) or National Institutes of Health (NIH), not physicians, and certainly not patients desperately in need of new therapies.

The process is hugely expensive and incredibly slow. According to the Tuft's Center for the Study of Drug Development, the average cost of bringing a new prescription drug from lab to market now tops $2.5 billion and takes more than 10 years.

That can make for a real thrill ride where investors are concerned, as share price for a pre-profit biotech can rise and fall dramatically and unpredictably with every related data release, financial report, news item, or regulatory hiccup over an entire decade, making long-term investment a crapshoot, at best.

But new regulations on the table could change everything for biotech investors and critically ill patients...